A new hope for patients with Huntington's disease?
On Sept 24, a gene therapy company uniQure released preliminary positive data from its pivotal phase 1/2 trial of AMT-130, a novel treatment for Huntington's disease. The announcement sparked widespread discussion in the medical community and renewed hope among patients with Huntington's disease and clinicians. Huntington's disease so far has been thought to be an incurable disease with little recent progress in the development of new treatment modalities.
Authors
- eClinicalMedicine
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103612
- Citations
- 2
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.82